News

AbbVie (NYSE: ABBV), a pharmaceutical leader, has faced some challenges over the past three years. The company is managing some patent cliffs and clinical setbacks that worried investors and dinged

If you see news about the pharmaceutical industry today and it isn't directly about GLP-1 weight loss drugs, it's likely to include at least a mention of this new class of medications. GLP-1 drugs

Pfizer (NYSE: PFE) is deeply unloved today. There are a couple of reasons for this that are important, but the big story revolves around the company's drug portfolio. With three drugs facing patent

After lagging the market over the past couple of years, Merck (NYSE: MRK) has experienced a slight rebound in the last month, thanks to several positive developments. The stock has increased by 20%

On November 14, California-based Tensile Capital Management disclosed a buy of 160,559 shares of Vertex (NASDAQ:VERX) in the third quarter. Despite the expanded stake, the market value of the

There are compelling reasons for some investors to consider investing in Medtronic (NYSE: MDT), depending on their goals and risk tolerance. It is a well-established healthcare leader that generates

On November 14, New York City-based Newtyn Management disclosed a purchase of 994,332 shares of QuidelOrtho Corporation (QDEL), increasing its stake by approximately $30.4 million.

According to a

Merck (NYSE: MRK) has taken its shareholders on a wild ride of late -- from last March's record high of more than $130 to this May's low near $76 back to its current price of just a little more than

Vertex Pharmaceuticals (NASDAQ: VRTX) has grown revenue and profit into the billions of dollars thanks to its expertise in the treatment of cystic fibrosis (CF). The company has developed a

It's inaccurate to call the largest health insurer in the country and the fourth-largest healthcare company by market cap an underdog. However, UnitedHealth Group (NYSE: UNH) looked more like an

Pharmaceutical stocks have been on fire this year. The iShares U.S. Pharmaceuticals ETF (NYSEMKT: IHE), which tracks 43 drugmakers, is up almost 29% year to date and 11% over the past month.

There

The pharmaceutical industry is highly competitive, and currently, the leading company in the sector is likely Eli Lilly (NYSE: LLY). That's driven by the fact that Eli Lilly makes the weight loss

Are things finally looking up for Merck (NYSE: MRK)? After being mostly southbound for the better part of the last two years, the pharmaceutical giant is showing signs of life. Over the past month

The past few years have been a challenging ride for Pfizer (NYSE: PFE). Since the company made history in 2022, when it became the first in the biopharma industry to reach $100 billion in annual

Vertex Pharmaceuticals (NASDAQ: VRTX) has proven itself to be an excellent long-term investment, advancing 91% over the past five years. This is as the company has delivered steady growth in revenue

One effective way to earn solid, long-term returns is to invest in dividend-paying stocks since reinvesting the payout can help boost stock performance. However, they aren't all created equal, and

Medtronic (NYSE: MDT), a medical device specialist, has lagged the market over the past five years. The company has experienced slow revenue growth, significant competition in some of its niches --

An analyst's price target increase for UnitedHealth Group (NYSE: UNH) stock was taken to heart by investors on Wednesday. Following news of the boost, they collectively pushed the large health insur

For years, UnitedHealth Group (NYSE: UNH) has been one of the best growth stocks to own on the New York Stock Exchange. A leading health insurance company, it generated solid and continuous growth

UnitedHealth (NYSE: UNH) stock is testing the patience of investors.

*Stock prices used were the afternoon prices of Nov. 28, 2025. The video was published on Nov. 30, 2025.

Continue reading

Source

New investing trends pop up on Wall Street all the time. Over the past seven years, we have witnessed excitement surrounding cannabis stocks, the metaverse, artificial intelligence, and more

The U.S. healthcare industry has been a lightning rod for controversy for years, but it's especially murky right now.

A political battle continues within the U.S. government over renewing expired

Earnings season always creates short-term winners and losers. Beverage behemoth Coca-Cola (NYSE: KO) and biotech giant Amgen (NASDAQ: AMGN) were firmly in the former category, as both delivered